| 000 | 01512 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250515023913.0 | ||
| 264 | 0 | _c20070604 | |
| 008 | 200706s 0 0 eng d | ||
| 022 | _a1471-4892 | ||
| 024 | 7 |
_a10.1016/j.coph.2006.03.004 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGasser, Jürg A | |
| 245 | 0 | 0 |
_aThe relative merits of anabolics versus anti-resorptive compounds: where our targets should be, and whether we are addressing them. _h[electronic resource] |
| 260 |
_bCurrent opinion in pharmacology _cJun 2006 |
||
| 300 |
_a313-8 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAccidental Falls _xprevention & control |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xpharmacology |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aBone Density _xdrug effects |
| 650 | 0 | 4 |
_aBone Density Conservation Agents _xpharmacology |
| 650 | 0 | 4 |
_aBone Regeneration _xdrug effects |
| 650 | 0 | 4 |
_aBone Resorption _xprevention & control |
| 650 | 0 | 4 | _aCathepsin K |
| 650 | 0 | 4 |
_aCathepsins _xpharmacology |
| 650 | 0 | 4 | _aDenosumab |
| 650 | 0 | 4 |
_aDiphosphonates _xpharmacology |
| 650 | 0 | 4 | _aExercise Therapy |
| 650 | 0 | 4 |
_aFractures, Bone _xetiology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aOsteoporosis _xcomplications |
| 650 | 0 | 4 | _aRANK Ligand |
| 650 | 0 | 4 |
_aTeriparatide _xpharmacology |
| 773 | 0 |
_tCurrent opinion in pharmacology _gvol. 6 _gno. 3 _gp. 313-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.coph.2006.03.004 _zAvailable from publisher's website |
| 999 |
_c16252941 _d16252941 |
||